NcXHF

ABLATIVE THERAPY FOR OLIGOMETASTATIC BREAST CANCER
ated patients: results of a proof of priniciple trial. Int J Radiat Oncol Biol
Phys. 2008;72:S6-S7.
46. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of
the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:
925-931.
47. Treasure T. Oligometastatic cancer: an entity, a useful concept, or a
therapeutic opportunity? J R Soc Med. 2012;105:242-246.
48. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with
autologous hematopoietic stem-cell transplantation in metastatic breast
cancer: overview of six randomized trials. J Clin Oncol. 2011;29:3224-3231.
49. Lewis SL, Porceddu S, Nakamura N, et al. Defınitive stereotactic
body radiotherapy (SBRT) for extracranial oligometastases: an international
survey of 1000 radiation oncologists. Am J Clin Oncol.
Epub 2015 Feb 2.
50. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for
oligometastases. Lancet Oncol. 2013;14:e28-e37.
51. Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotactic ablative radiotherapy
for comprehensive treatment of oligometastatic tumors
(SABR-COMET): study protocol for a randomized phase II trial. BMC
Cancer. 2012;12:305.
52. Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes
oligometastasis(es). PLoS One. 2011;6:e28650.
53. Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic
progression in lung metastasis(es) patients is associated with specifıc
microRNAs. PLoS One. 2012;7:e50141.
54. Solanki AA, Weichselbaum RR, Appelbaum D, et al. The utility of FDG-
PET for assessing outcomes in oligometastatic cancer patients treated
with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012;
7:216.
55. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J Med.
2004;351:781-791.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e15